2010
Potential Psychiatric Applications of Metabotropic Glutamate Receptor Agonists and Antagonists
Krystal JH, Mathew SJ, D’Souza D, Garakani A, Gunduz-Bruce H, Charney DS. Potential Psychiatric Applications of Metabotropic Glutamate Receptor Agonists and Antagonists. CNS Drugs 2010, 24: 669-693. PMID: 20658799, DOI: 10.2165/11533230-000000000-00000.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsPreliminary clinical trialsPositive allosteric modulatorsPsychiatric disordersClinical trialsAnimal modelsAllosteric modulatorsGroup II mGluR agonistGroup IMetabotropic glutamate receptor agonistAnxiety disordersPotential psychiatric applicationsGlutamate receptor agonistsMetabotropic glutamate receptorsTreatment of schizophreniaRole of glutamateForm of depressionMGluR agonistAntidepressant propertiesMGluR5 agonistReceptor agonistGlutamate receptorsMood disordersArea of schizophreniaPromising agentAgonists
2008
Short-term tolerability of a nonazapirone selective serotonin 1A agonist in adults with generalized anxiety disorder: A 28-day, open-label study
Mathew SJ, Garakani A, Reinhard JF, Oshana S, Donahue S. Short-term tolerability of a nonazapirone selective serotonin 1A agonist in adults with generalized anxiety disorder: A 28-day, open-label study. Clinical Therapeutics 2008, 30: 1658-1666. PMID: 18840371, DOI: 10.1016/j.clinthera.2008.09.006.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultAgedAnti-Anxiety AgentsAnxiety DisordersDiagnostic and Statistical Manual of Mental DisordersDrug Administration ScheduleFemaleHumansMaleMiddle AgedPiperazinesPsychiatric Status Rating ScalesSerotonin 5-HT1 Receptor AgonistsSerotonin Receptor AgonistsSingle-Blind MethodSulfonamidesSurveys and QuestionnairesTreatment OutcomeConceptsGeneralized anxiety disorderShort-term tolerabilityAdverse eventsPRX-00023Hamilton Anxiety Rating Scale scoresVital signsResponse criteriaAnxiety disordersTotal scoreOpen-label studySerotonin 1A agonistSingle-blind placeboAnxiety Rating Scale scoresSerious adverse eventsStudy end pointInfluenza-like symptomsOpen-label treatmentPrimary outcome measureDiagnosis of GADRating Scale scoresEnd point changeSample of patientsSerotonin 1A receptorPremature ventricular contractionsSelective partial agonist